- Research Article
- 10.1016/j.ijtb.2026.02.012
Landscape of metagenomics: fight against tuberculosis and other infectious disease in India.
- Jan 01, 2026
- The Indian journal of tuberculosis
- Bineeta Kashyap + 4 more +4
Publications from 2021 to 2026
Showing 10 of 67 papers
Landscape of metagenomics: fight against tuberculosis and other infectious disease in India.
NMR based human gut metabolomic profiling reveals altered metabolites associated with pulmonary and extra-pulmonary tuberculosis.
Tuberculosis remains one of the world's deadliest infectious diseases. The pathophysiology of the two manifestations of Mycobacterium tuberculosis infection, pulmonary TB (PTB) and extrapulmonary TB (EPTB) is still not fully understood. Understanding the metabolic profile of both disease manifestations in patients is important for developing therapeutic approaches and molecular diagnosis. The current study aimed to elucidate differences in the gut metabolic profile of PTB and EPTB patients compared to healthy controls (HCs). We used an untargeted approach through 1H Nuclear Magnetic Resonance (NMR) spectroscopy to perform metabolomic profiling of stool samples from 77TB patients [pulmonary TB (PTB, n = 33), cervical lymph node TB (CrLNTB, n = 30), abdominal TB (ATB, n = 14)], and 30 HCs. Multivariate and univariate analyses were performed to identify the differential gut metabolites associated with TB patients. PTB patients showed greater metabolic perturbation than either EPTB group, with 24 metabolites significantly altered compared to 13 in ATB and 12 in CrLNTB, relative to HCs (adjusted p < 0.05). Each TB subtype displayed distinct metabolic profiles, yet several metabolites were commonly altered across all TB groups, including valine, N-formyl-L-methionine, choline, dimethylsulfone, tryptophan, valerate, N-acetylglutamate, creatine, and malonate. In the combined TB cohort versus controls, the most discriminatory metabolites were valine and N-formyl-L-methionine (AUC ≥ 0.80). Overall, these findings offer insights into the gut metabolome of TB patients in India and characterize for the first time metabolic perturbations in EPTB patients. The study highlights the metabolic disruptions associated with PTB and EPTB patients.
Read moreEarly preclinical development of Mycobacterium tuberculosis amino acid biosynthesis pathway inhibitor DRILS-1398 as a potential anti-TB drug.
The search for new anti-tubercular agents is vital for the fight against Mycobacterium tuberculosis, particularly given the rise of drug-resistant strains. DRILS-1398, a pyrazolo[4,3-d]pyrimidine derivative, was discovered as a potent inhibitor of M.tb chorismate mutase (M.tb-CM) with an IC50 = 3.0 ± 0.2 μM (n = 3) and IC90 = 10 μM. The compound demonstrated efficacy against multi-drug resistant M.tb strains (MIC = 4 μg/mL, ∼10.0 μM) and effective inhibition of intracellular M.tb in THP-1 macrophages. With favorable pharmacokinetics, moderate stability in vitro, and a promising safety profile, DRILS-1398 showed no toxicity at doses up to 500 mg/kg b.w./day when dosed orally daily once for 7 consecutive days in mice. Both DRILS-1398 and its formulation DRILS-1398(F) were successful in clearing M.tb infection from the lungs and spleen in murine models. These findings suggest DRILS-1398 as a promising lead candidate for developing a first-in-class anti-tubercular drug.
Read morePrevalence and Geographical Distribution of Various Nontuberculous Mycobacterial (NTM) Species/Subspecies in India: Early Findings of Indian Council of Medical Research (ICMR), New Delhi Sponsored Multicentre Research Project Between 2021-2024
Abstract Rationale: Prevalence of nontuberculous mycobacterial (NTM) disease is increasing globally. In high-TB-burden countries because of similarities with TB, NTM disease is usually not considered in the differential diagnosis and treated as TB. A prospective multicentre study was conducted at six sites in five states of India between 2021-2024 to determine prevalence of NTM disease and geographic variation of NTM species/subspecies among TB-suspects. Methods: The study was performed on GeneXpert MTB/RIF (Cepheid, USA) negative pulmonary and extrapulmonary specimens applying inclusion and exclusion criteria. All participating centres obtained ethical clearance. Written informed consent was obtained from all study patients. The confirmed NTM isolates (negative on SD-MPT64TB Ag immunochromatography kit, Standard Diagnostics, South Korea) were subjected to GenoType®-mycobacterium common mycobacteria/additional species and GenoType®-NTM-DR line probe assay (LPA) kits (Hain Lifescience, Germany) for NTM species/subspecies identification and were later validated by whole genome sequencing (WGS, Illumina-MiSeq sequencing using Nextra XT-DNA Library Prep protocol, USA). Demographic and other clinical details were carefully recorded. American Thoracic Society 2007 and 2020 guidelines were followed for NTM diagnosis. Results: NTM were isolated from 226 patients [NTM-pulmonary-disease (NTM-PD)=187; extrapulmonary-NTM (EPNTM)=39] among 71,143 TB-suspects with a prevalence of 0.32%. Of these 138(61%) were male. The median time to diagnose NTM was 119.7 days (IQR=57.1-132.1). The mean age of patients was 46.1 years (range=12-73). The mean body mass index (BMI) was 23.1 kg/m2(SD=3.1) and 39.8% (90/226) patients had BMI &lt;18.5 kg/m2. Overall isolated NTM species included: M.avium complex (MAC) (n=58; M.intracellulare=38, M.avium=20), M.abscessus (n=56; M.abscessus subsp. abscessus=29, M.abscessus subsp. massiliense=25, M.abscessus subsp. bolletii=2), M.fortuitum (n=46), M. kansasii (n=45), M. simiae (n=11), M. gordonae (n=7) and one each of M.lentiflavum, M.senegalense and M.mucogenicum. LPA showed 97.6% (122/125) concordance with WGS results in NTM species/subspecies identification. One clarithromycin-resistant M.abscessus subsp. abscessus isolate [T28 sequevar of erm (41) gene] was identified by LPA and WGS. In NTM-PD, species isolated were MAC (27.8%;52/187), M.kansasii (24.1%;45/187), M.abscessus (21.4%; 40/187), M.fortuitum (16%;30/187), M.simiae (5.9%;11/187), M.gordonae (3.7%;7/187), M.mucogenicum (0.5%;1/187) and M.lentiflavum (0.5%;1/187). In EPNTM, M.abscessus (41%;16/39), M.fortuitum (41%;16/39), MAC (15.4%;6/39) and M.senegalense (2.6%;1/39) were commonest species. Following regional variations of NTM species were noted: MAC was predominantly isolated from north and south Indian states, M.kansasii, and M.abscessus from western and central states respectively. Conclusion: This is the first comprehensive Indian study describing prevalence and geographical variation of NTM species/subspecies among TB-suspects.LPA can be safely recommended for NTM diagnosis in high-TB-burden countries.
Read morePrenatal Diagnosis of Congenital Intra-abdominal Aorto-Umbilical Arteriovenous Fistula in a Case of Trisomy 21
Why have we failed in controlling tuberculosis: Historical debate?
Evaluation of GeneNAT Real-Time Polymerase Chain Reaction Analyzer and Pre-loaded Chip-Based Mycobacterium tuberculosis and Multidrug-Resistant Tuberculosis Detection in the Diagnosis of Pulmonary Tuberculosis.
Tuberculosis (TB) is still the second causative agent of death worldwide after COVID-19. It is caused by Mycobacterium tuberculosis (MTB) infection. The aim of the current study was to compare the performance of GeneNAT real-time polymerase chain reaction analyzer and pre-loaded chip-based MTB screening and multidrug-resistant tuberculosis (MDR-TB) detection kit (Smart SureTM MTB & MDR-TB, Genetix Biotech Asia Pvt. Ltd., New Delhi, India) against the established WHO-approved GeneXpert Ultra (MTB/rifampicin (RIF)), line probe assay (LPA), and mycobacteriagrowthindicatortube(MGIT) culture at point of care (POC) level. A total of 450 pulmonary TB (PTB) suspect patients were enrolled from October 2023 to March 2024 at the Intermediate Reference Laboratory, Department of Medicine, All India Instituteof Medical Sciences, New Delhi, India. GeneXpert and GeneNAT tests were done directly from sputum specimens. However, processed sputum specimens were used for both LPA (GenoType MTBDRplus) and liquid culture and drug susceptibility testing (MGIT culture and drug susceptibility testing (DST)). On comparing with GeneXpert, for the detection of MTB and rifampicin (RIF), Smart SureTM showed a sensitivity of 98.18% and 97.5% with a specificity of 100% and 98.92%, respectively. While comparing mutations in therpoB gene with LPA, the Smart SureTM MDR-TB kit exhibited sensitivity and specificity of 96.77% and 99.12%, respectively. For katG and inhA genes, sensitivity and specificity were 97.6% & 85.71% and 98.66% & 98.01%, respectively, for both genes. Smart SureTM MDR-TB showed comparable results with MGIT-DST with sensitivity and specificity of 96.88% & 96.15% and 98.99%& 99.02%, respectively, for both RIF and isoniazid (INH) drugs. The GeneNAT system test may provide the status of RIF and INH resistance in PTB cases in a short time with the use of minimal specimens. It required very little infrastructurewith less skilled laboratory staffin comparison with other WHO-approved diagnostics used in resource-limited countries with TB and drug-resistant TB burdens.
Read moreAdult Pleural Tuberculosis
Adult Pleural Tuberculosis
Adult Musculoskeletal Tuberculosis
Adult Musculoskeletal Tuberculosis
Self-driven solutions and resilience adapted by people with drug-resistant tuberculosis and their caregivers in Bengaluru and Hyderabad, India: a qualitative study